A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Anagrelide is a drug that has been shown to slow down how fast platelets are made in the bone
marrow, and has been approved by the FDA for treating high platelets counts in patients with
bone marrow disorders.
Anagrelide Controlled Release ("CR") is a new preparation of anagrelide that is made to
dissolve more slowly than currently marketed versions of this drug. Because of this, the
anagrelide is taken up into the blood more slowly. Researchers think that this slower release
of the drug could help to lower side effects that might be caused by high blood levels when
the drug dissolves as quickly as it does with the currently marketed product.
The main purposes of this study are to see how well Anagrelide CR can control platelet counts
in patients with high platelet levels, to see what kind of side effects it causes, and to
measure blood levels of the drug.